• Tran CG, Dornbush C, Jensen BS, Mott SL, Fannon EEH, Stark AC, Mali ME, Berg DJ, Talbert EE, Chan CHF. “Survival Benefit of Obesity in Stage IV Colorectal Cancer: Better Tolerability of Chemotherapy? -A Retrospective Study”. *In press at BMC Cancer, January 22, 2026
  • Xiao S^, Freeman A, Kalmanek E, Steckly K, Belding-Schmitt M, Chan CHF, Talbert EE*. “Skeletal Muscle Mass Associates with Pancreaticoduodenectomy Operative Time in a Sex-dependent Manner”. BMC Cancer 25(1):1889 (2025).
  • Weinzierl NM^, Putri J, Spitler KM, Talbert EE*. “Sex-specific survival but not tissue wasting in the KPP mouse model of pancreatic cancer-induced cachexia”. J Appl Physiol 139(5):1189-1194 (2025).
  • Oles AR, Yu PY, Udeme AA, Sharma S, Londhe P, Pryce BR, Talbert EE, Hill EM, Miranda CJ, Kaspar BK, Arnold MA, Hyland J, London CA, Houghton PJ, Wang DJ, Roberts RD, Guttridge DC. MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. iScience 28(8):113149 (2025).
  • Goncalves MD, Dunne RF, Moore AC, Phillips W, Heymsfield SB, Brown JC, Talbert EE, Janowitz T. “Call to Improve Coding of Cancer-Associated Cachexia.” JCO Oncol Pract.21(7):926-931 (2025).
  • Pryce BR, Oles A, Talbert EE, Romeo MJ, Vaena S, Sharma S, Spadafora V, Tolliver L, Mahvi DA, Morgan KA, Lancaster WP, Beal E, Koren N, Watts B, Overstreet M, Berto S, Subramanian S, Calisir K, Crawford A, Neelon B, Ostrowski MC, Zimmers TA, Tidball JG, Wang DJ, Guttridge DC. “Muscle inflammation is regulated by NF-κB from multiple cells to control distinct states of wasting in cancer cachexia.” Cell Rep. 43(11):114925 (2024).
  • Spadafora V, Pryce BR, Oles A, Talbert EE, Romeo M, Vaena S, Berto S, Ostrowski MC, Wang DJ, Guttridge DC. “Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia” BMC Cancer 24(1):414 (2024). 
  • Kazarian AG^, Conger HK^, Mott SL, Loeffler BT, Dempewolf SM, Coleman KL, Pearlman AM, Chan CHF*, Talbert EE*. “Retrospective study of testosterone deficiency and symptom burden in patients with pancreatic cancer” Transl Androl Urol 12(7):1079-1089 (2023). 
  • Clamon G, Byrne MM, Talbert EE. “Inflammation as a Therapeutic Target in Cancer Cachexia”. Cancers. 14(21), 5262 (2022).
  • Chakedis JM, Dillhoff ME, Schmidt CR, Rajasekera PV, Evans DC, Williams TM, Guttridge DC*, Talbert EE*. “Identification of circulating plasma ceramides as a potential sexually dimorphic biomarker of pancreatic cancer-induced cachexia.” JCSM Rapid Communications 5: 254-265 (2022).
  • Talbert EE, Guttridge DC. “Emerging Signaling Mediators in the Anorexia-Cachexia Syndrome of Cancer” Trends Cancer. 8(5):397-403 (2022).
  • Talbert EE, Cuitiño MC, Ladner KJ, Rajasekera PV, Siebert M, Shakya R, Leone GW, Ostrowski MC, Paleo B, Weisleder N, Reiser PJ, Webb A, Timmers CD, Eiferman DS, Evans DC, Dillhoff ME, Schmidt CR, Guttridge DC. “Modeling Human Cancer-induced Cachexia”. Cell Rep. 6;28(6):1612-1622 (2019).
  • Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA. “Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.” Pancreatology. S1424-3903(18)30747-6 (2018).
  • Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC. “Circulating MCP-1 is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer Patients”. J Cachexia Sarcopenia Muscle. 9(2):358-368 (2018).
  • Lewis HL, Chakedis JM, Talbert E, Haverick E, Rajasekera P, Hart P, Bloomston M, Dillhoff M, Pawlik TM, Guttridge D, Schmidt CR. “Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma”. J Surg Oncol. 117(6):1260-1266 (2018).
  • Talbert EE*, Yang J*, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, and Lesinski GB. “Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through Both Tumor Extrinsic and Intrinsic Activities” Mol Cancer Ther 16(2):344-356 (2017).
  • Talbert EE, Guttridge DC. “Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.” Semin Cell Dev Biol. 54:82-91 (2016).

  • Talbert EE*, Metzger GA*, He WA, Guttridge DC. “Modeling human cancer cachexia in colon 26 tumor-bearing mice.” J Cachexia Sarcopenia Muscle. 5(4):321-8 (2014).